Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus
prednisone with placebo plus prednisone in patients with metastatic castration-resistant
prostate cancer (CRPC) who have failed one or two chemotherapy regimens. At least one of the
previous chemotherapies must have contained docetaxel.